Thus, DPP-4 inhibition may have the potential to counteract the DPP-4-mediated SARS-CoV-2 hijacking and virulence and to improve clinical outcomes of COVID-19 by interfering with the interaction between SARS-CoV-2 and target host cells [60–62]. Here, DPP4 is linked to COVID-19.